Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
At a new lawsuit, a scientist of the liver resumption of diseases
Arun Sanyal, Doctor of Medical Sciences, Director of the Institute of VKO Petro-Sanil on Liver and Metabolic Health, discusses a clinical study involving 800 participants, in which the weekly dose of semaglutide was effective in the treatment of fat liver diseases.
With the help of Semaglutid’s injectionsScientists have been able to change life -threatening cases in a new clinical test published in the New England Journal of Medicine.
Semaglutide, which is traditionally the treatment of type 2 diabetes, was provided to a participant who was diagnosed with life -threatening liver disease called metabolic dysfunction associated with steathepatitis (MASH).
“This is the main step forward in this field,” said Arun Sanyal, MD, director of the Institute of the Center for Liver and Metabolic Health, in a video from VKA. “It gives patients extra choice when we think about treatment A fatty liver disease“
Joe Rogan refused to consume alcohol for this simple reason
MASH-is a severe form of metabolic dysfunction associated with steateotic liver disease (Masld), which was previously known as non-alcoholic liver fat, Webmd reports.
MASH-is a severe form of metabolic dysfunction associated with steateotic liver disease (Masld), which was previously known as a non-alcoholic ingle disease of the liver. (Istock)
Both Mash and Masld are marked by excessive fat in the liver, which can be dangerous.
“Over time, the accumulation of fat in the liver can lead to inflammation, liver fibrosis, cirrhosis and liver cancer,” the press release said.
The first GLP-1 pill for weight loss, diabetes shows success in the late phase test
Researchers have decided to explore semaglutide as potential treatment because it had previously been shown that this drug class reduces fat and liver scars for people with MASH.
Between 2021 and 2023, 800 randomly selected participants in 37 countries, which came once a week, either Semaglutid or placebo, the press release said. More than half were Diabetes type 2 And about 75% were obese.
Participants receiving semaglutide had improvement of liver enzymes and other liver fibrosis measures, as well as 10.5% weight loss. (Istock)
After 72 weeks of treatment, 62.9% of participants were less inflammation and fat accumulation in their liver.
In the placebo group, only 34.3% of the participants felt a decrease in symptoms.
“The liver actually starts to look much better under the microscope in these patients,” Sanyal said.
Ozempic, other semaglutides associated with hair loss: That’s what you need to know
Researchers also found that 36.8% of the semaglutide group found improvement of liver fibrosis against 22.4% in the placebo group.
Participants receiving semaglutid also saw improvement of liver enzymes and blood fibrosis measures 10.5% weight loss.
“I have been working with GLP-1 procedures for 16 years and these results are very exciting.”
Some adverse impressions were more common in the Semaglutide group, including nausea, diarrhea, constipation and vomiting.
“Novo Nordisk continues to explore semaglutid through metabolic and cardiovascular healthIncluding MASH, a condition with disabilities for patients and healthcare providers, “said Anna Windle, a doctoral degree, senior vice -president for clinical development, medical and regulatory affairs in Novo Nordisk, manufacturers of Ozempic and Wegovy, in the press -release.
Click here to subscribe to our health newsletter
“We are recommended by these published conclusions in Nejm and what it can mean for patients. Based on this data, we look forward to working with the normative organs to bring this new potential treatment for patients.”
“Although these results should be treated with caution, the analysis shows that Semaglutide can be an effective tool for the treatment of this advanced liver disease,” said the trial leader. (Istock)
“Although these results should be treated with caution, the analysis shows that Semaglutide can be an effective tool for the treatment of this advanced liver disease,” said the leading researcher Philip News, director of the liver institution Roger Williams.
Click here to get the Fox News app
“I have been working with GLP-1 procedures for 16 years, and these results are very exciting,” he added.
Sanyal noted that the Semaglutide was previously shown for obesityDiabetes and heart disease.
“Now we can add liver disease to this list.”
For additional health articles visit www.foxnews.com/health
Going forward, the research group plans Collect the data From almost 1200 participants in 37 countries to five years to determine the influence of Semaglutid on long -term liver complications.
